

Anti-Herpesvirus Activities of *Pseudomonas* sp. S-17 Rhamnolipid and its Complex with Alginate

Mimi Remichkova^{a,*}, Danka Galabova^a, Ivana Roeva^a, Elena Karpenko^b, Alexander Shulga^b, and Angel S. Galabov^a

^a The Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, 26 Acad. Georgi Bonchev Str., 1113 Sofia, Bulgaria. Fax: +35928700109.
E-mail: mimi_remichkova@yahoo.com

^b Department of Physical-Organic Chemistry, Academy of Sciences of Ukraine, Lviv, Ukraine

* Author for correspondence and reprint requests

Z. Naturforsch. **63c**, 75–81 (2008); received June 12/August 6, 2007

The rhamnolipid biosurfactant PS-17 and its complex with the polysaccharide alginate, both produced by the *Pseudomonas* sp. S-17 strain, were studied for their antiviral activity against herpes simplex virus (HSV) types 1 and 2. They significantly inhibited the herpesvirus cytopathic effect (CPE) in the Madin-Darby bovine kidney (MDBK) cell line. The investigations were carried out according to the CPE inhibition assay protocol. The suppressive effect of the compounds on HSV replication was dose-dependent and occurred at concentrations lower than the critical micelle concentration of the surfactant. The 50% inhibitory concentration (IC₅₀) of rhamnolipid PS-17 was 14.5 µg/ml against HSV-1 and 13 µg/ml against HSV-2. The IC₅₀ values of the complex were 435 µg/ml for HSV-1 and 482 µg/ml for HSV-2. The inhibitory effects of the substances were confirmed by measuring the infectious virus yields with the multicycle virus growth experimental design as well: Δlog CCID₅₀ of 1.84–2.0 against the two types of herpes simplex viruses by rhamnolipid PS-17 (20 µg/ml), and a strong reduction of the HSV-2 virus yield under the effect of the alginate complex at a concentration of 450 µg/ml. The results indicate that rhamnolipid PS-17 and its alginate complex may be considered as promising substances for the development of anti-herpetic compounds.

Key words: Herpes Simplex Virus, Rhamnolipid, Alginate